innovator to know

Deloitte names new Houston-based O&G leader with focus on innovation and inclusion

Amy Chronis, who oversees the Houston office for Deloitte, has a new role she will be adding on to her plate. Photo courtesy Deloitte/AlexandersPortraits.com

Amy Chronis has had a big year. First, she took over as the Greater Houston Partnership's 2021 chair. And on February 25 she was named a vice chairman of Deloitte LLP and leader of its oil, gas, and chemicals sector.

In her new role, Chronis will lead the overall strategic direction of Deloitte's oil and gas arm while she continues to serve as managing partner of the company's Houston office. She succeeds Duane Dickson, who will be retiring from the leadership role in May.

Chronis is a licensed CPA and known to be a thought leader in aspects of the energy transition with a 30-year background in the oil and gas, technology, and manufacturing industries.

"Our industry is at a crossroads and going through one of the most challenging business environments on record," Chronis said in a statement. "It's an honor to take on this role at such a pivotal time for our oil, gas and chemicals clients engaging in the energy transition and emerging from the pandemic. I look forward to helping them navigate the winding road ahead."

Chronis spoke with InnovationMap earlier this year about Houston's evolving image and impressive innovation in the health, space, and energy industries that often gets overlooked.

"Houston needs to step up and state our case as often as possible," she told InnovationMap last month.

Chronis is also an advocate for inclusion in the workplace. She co-leads the Houston cohort of Deloitte's Board Ready Women and Women on Boards programs and will aim to advance Deloitte's diversity, equity, and inclusion efforts in her new role.

Click here to read a run down of Chronis's address to the GHP earlier this year.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted